Pegetron [peginterferon alfa-2b] Redipen [ribavirin] Prospective Optimal Weight-Based Dosing Response Program.

Trial Profile

Pegetron [peginterferon alfa-2b] Redipen [ribavirin] Prospective Optimal Weight-Based Dosing Response Program.

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Feb 2016

At a glance

  • Drugs Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms RediPEN
  • Sponsors Merck & Co; Schering-Plough
  • Most Recent Events

    • 06 Feb 2016 Results (post hoc pooled analysis of PoWer and RediPEN studies) published in the European Journal of Clinical Microbiology and Infectious Diseases (n = 1242).
    • 31 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Jun 2012 Planned number of patients changed from 1285 to 2320 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top